Dompé funded the charities that paid its own drug's copays. It cost $32 million.

By ··1 min read·2 sources

The company reported itself and got credit for it. The admissions it signed show how the arrangement was built around the launch of Oxervate.

Dompé U.S. agreed on September 10, 2026, to pay $32 million over Medicare copays for its eye drug Oxervate. The government said that from 2018 to 2021 Dompé paid those copays through two patient assistance foundations to induce purchases, which the Anti-Kickback Statute forbids.

The admissions are specific. Employees had reservations about launching before a foundation payment was in place. Two foundations opened funds covering Oxervate copays after conversations with Dompé staff, and Dompé then contributed to them. It also sought patient-assistance data from the foundations and its hub pharmacy.

The Italian parent disclosed the conduct itself, and the discount was large. About $29 million of the total is restitution, a multiplier of roughly 1.1 times the loss where the statute allows three. There is no finding of liability.

So the penalty for routing Medicare money through a charity for three years was the money back plus about a tenth. Self-reporting is worth encouraging, but at that price the deterrent is thin.

Sources

  1. justice.gov · justice.gov/opa/pr/dompe-us-agrees-pay-32m-resolve-false-claims-act-liability-relating-sel…
  2. arnoldporter.com · arnoldporter.com/en/perspectives/blogs/fca-qui-notes/posts/2026/09/semi-sweet-charity-domp…

Cite this report

The Precedent. "Dompé funded the charities that paid its own drug's copays. It cost $32 million.." September 30, 2026. https://theprecedent.org/article/dompe-funded-the-charities-that-paid-its-own-drugs-copays-it-cost-32-million